Head and Neck Cancer
ALLIANCE / A092105
Official Title: Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Advanced Nasopharyngeal Cancer
Study Purpose: To determine if progression-free survival is more favorable with triplet therapy combination of Cabozantinib + Nivolumab + Ipilimumab than with doublet therapy combination of Nivolumab + Ipilimumab
Status:
Recruiting